Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials

Maura Marcucci, Federico Germini, Anna Coerezza, Luca Andreinetti, Lorenzo Bellintani, Alessandro Nobili, Paolo Dionigi Rossi, Daniela Mari, Maura Marcucci, Federico Germini, Anna Coerezza, Luca Andreinetti, Lorenzo Bellintani, Alessandro Nobili, Paolo Dionigi Rossi, Daniela Mari

Abstract

Background: Chronic pain in older people is highly prevalent, often underestimated, and associated with adverse outcomes. Most available analgesic drugs are often either ineffective or not tolerated, with many side effects. Palmitoylethanolamide (PEA) is an endogenous widely distributed N-acylethanolamina involved in neuroinflammation and pain-generating processes. Formulations containing ultra-micronized palmitoylethanolamide (um-PEA) are available but their effectiveness on chronic pain in highly heterogeneous geriatric patients is not clear and probably not generalizable. We planned to adopt the N-of-1 trial approach to test the effectiveness of um-PEA objectively at the individual level in our older outpatients.

Methods/design: Persons 65 years or older referring to the Geriatric Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan complaining of noncancer chronic pain of any origin will be eligible. Each trial will be a placebo-controlled randomized crossover trial including two um-PEA (600 mg twice a day) and placebo treatment pairs. The um-PEA or placebo 3-week periods will be separated by 2-week washout intervals to overcome possible carryover effects. Pain intensity, need of on-demand analgesic medications, and impact on daily activities will be evaluated. Cognitively impaired patients will be eligible as long as an expression of pain can be recognized and its frequency assessed by a caregiver. Trial results will be discussed with the patient or caregiver and the treating physician to decide whether to continue the treatment. The impact of the N-of-1 approach on the physician's management plan and confidence will be assessed. We will secondarily meta-analyze the performed N-of-1 trials to obtain an estimate of the average effect of um-PEA compared with placebo using a frequentist and Bayesian approach.

Discussion: While pursuing an ultimate clinical objective, i.e. to empirically and objectively decide the best treatment choice for an individual older patient with chronic pain, these series of geriatric N-of-1 trials on PEA will bring the principles of evidence-based medicine into the care of patients not usually represented in conventional randomized controlled trials, and realize a patient-centered outcome approach necessary to improve appropriate prescribing in elderly patients with multimorbidity and polypharmacy.

Trial registration: ClinicalTrials.gov NCT02699281 . Registered on 3 March 2016.

Keywords: Aged; Analgesics; Chronic pain; Clinical trial; Elderly; Geriatric; N-of-1 trial; Normast; Palmitoylethanolamide.

Figures

Fig. 1
Fig. 1
SPIRIT Study diagram. Wn: week number, D: daily W: weekly. The study duration is 18 weeks. After the baseline assessment at time 0, patients will have two pairs of active drug (3 weeks) and placebo (3 weeks) exposures. Randomly assigned treatment pairs will comprise two treatment periods (active therapy or placebo) separated by a 2-week washout period. Treatment pairs will also be separated by washout periods
Fig. 2
Fig. 2
Pain assessment scale
Fig. 3
Fig. 3
Questionnaire for functional status assessment

References

    1. Andrade DC, Faria JW, Caramelli P, Alvarenga L, Galhardoni R, Siqueira SR, et al. The assessment and management of pain in the demented and non-demented elderly patient. Arq Neuropsiquiatr. 2011;69(2B):387–94. doi: 10.1590/S0004-282X2011000300023.
    1. Molton IR, Terrill AL. Overview of persistent pain in older adults. Am Psychol. 2014;69(2):197–207. doi: 10.1037/a0035794.
    1. Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer MC, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008;9(10):883–91. doi: 10.1016/j.jpain.2008.05.005.
    1. Denard PJ, Holton KF, Miller J, Fink HA, Kado DM, Marshall LM, et al. Back pain, neurogenic symptoms, and physical function in relation to spondylolisthesis among elderly men. Spine J. 2010;10(10):865–73. doi: 10.1016/j.spinee.2010.07.004.
    1. Donald IP, Foy C. A longitudinal study of joint pain in older people. Rheumatology. 2004;43(10):1256–60. doi: 10.1093/rheumatology/keh298.
    1. Mailis-Gagnon A, Nicholson K, Yegneswaran B, Zurowski M. Pain characteristics of adults 65 years of age and older referred to a tertiary care pain clinic. Pain Res Manag. 2008;13(5):389–94. doi: 10.1155/2008/541963.
    1. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–46. doi: 10.1111/j.1532-5415.2009.02376.x.
    1. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50(6 Suppl):S205–24.
    1. Grotle M, Brox JI, Vollestad NK. Functional status and disability questionnaires: what do they assess? A systematic review of back-specific outcome questionnaires. Spine. 2005;30(1):130–40. doi: 10.1097/01.brs.0000149184.16509.73.
    1. Paladini A, Fusco M, Coaccioli S, Skaper SD, Varrassi G. Chronic pain in the elderly: the case for new therapeutic strategies. Pain Physician. 2015;18(5):E863–76.
    1. Verdu E, Ceballos D, Vilches JJ, Navarro X. Influence of aging on peripheral nerve function and regeneration. J Peripher Nerv Syst. 2000;5(4):191–208. doi: 10.1046/j.1529-8027.2000.00026.x.
    1. Edwards RR, Fillingim RB, Ness TJ. Age-related differences in endogenous pain modulation: a comparison of diffuse noxious inhibitory controls in healthy older and younger adults. Pain. 2003;101(1–2):155–65. doi: 10.1016/S0304-3959(02)00324-X.
    1. Farrell M, Gibson S. Age interacts with stimulus frequency in the temporal summation of pain. Pain Med. 2007;8(6):514–20. doi: 10.1111/j.1526-4637.2007.00282.x.
    1. Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomized placebo controlled trials. BMJ. 2015;350:h1225. doi: 10.1136/bmj.h1225.
    1. Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2015;75(3):552–9. doi: 10.1136/annrheumdis-2014-206914.
    1. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002;29(4):804–12.
    1. Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomized trials. Ann Rheum Dis. 2007;66(3):417–8. doi: 10.1136/ard.2006.055012.
    1. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol. 2001;96(4):1019–27. doi: 10.1111/j.1572-0241.2001.03740.x.
    1. Setakis E, Leufkens HG, van Staa TP. Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis Rheum. 2008;59(8):1105–11. doi: 10.1002/art.23925.
    1. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:CD006605.
    1. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30. doi: 10.1016/j.jpain.2008.10.008.
    1. Soderberg KC, Laflamme L, Moller J. Newly initiated opioid treatment and the risk of fall-related injuries. A nationwide, register-based, case-crossover study in Sweden. CNS Drugs. 2013;27(2):155–61. doi: 10.1007/s40263-013-0038-1.
    1. American Geriatrics Society 2015 Beers Criteria Update Expert Panel American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46. doi: 10.1111/jgs.13702.
    1. Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manag. 2008;35(2):214–28. doi: 10.1016/j.jpainsymman.2007.03.015.
    1. Forsythe P, Bienenstock J. The mast cell-nerve functional unit: a key component of physiologic and pathophysiologic responses. Chem Immunol Allergy. 2012;98:196–221. doi: 10.1159/000336523.
    1. Mika J, Zychowska M, Popiolek-Barczyk K, Rojewska E, Przewlocka B. Importance of glial activation in neuropathic pain. Eur J Pharmacol. 2013;716(1–3):106–19. doi: 10.1016/j.ejphar.2013.01.072.
    1. Norden DM, Godbout JP. Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol. 2013;39(1):19–34. doi: 10.1111/j.1365-2990.2012.01306.x.
    1. Hains LE, Loram LC, Weiseler JL, Frank MG, Bloss EB, Sholar P, et al. Pain intensity and duration can be enhanced by prior challenge: initial evidence suggestive of a role of microglial priming. J Pain. 2010;11(10):1004–14. doi: 10.1016/j.jpain.2010.01.271.
    1. Esposito E, Cuzzocrea S. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. Mini Rev Med Chem. 2013;13(2):237–55.
    1. Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerdle B. Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain. 2013;154(9):1649–58. doi: 10.1016/j.pain.2013.05.002.
    1. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139(3):541–50. doi: 10.1016/j.pain.2008.06.003.
    1. Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets. 2013;12(1):34–44. doi: 10.2174/1871527311312010008.
    1. Gatti A, Lazzari M, Gianfelice V, Di Paolo A, Sabato E, Sabato AF. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med. 2012;13(9):1121–30. doi: 10.1111/j.1526-4637.2012.01432.x.
    1. Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med. 2011;102(2):141–7.
    1. Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain. 2012;26(2):99–104.
    1. Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623.
    1. Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, et al. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets. 2011;10(8):916–20. doi: 10.2174/187152711799219307.
    1. Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11–24.
    1. Larson EB. N-of-1 clinical trials: a technique for improving medical therapeutics. West J Med. 1990;152(1):52–6.
    1. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med. 2011;8(2):161–73. doi: 10.2217/pme.11.7.
    1. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S21–8. doi: 10.1016/j.jclinepi.2013.04.006.
    1. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The n-of-1 randomized controlled trial: clinical usefulness: our three-year experience. Ann Intern Med. 1990;112(4):293–9. doi: 10.7326/0003-4819-112-4-293.
    1. Maciejewski ML, Bayliss EA. Approaches to comparative effectiveness research in multimorbid populations. Med Care. 2014;52(Suppl 3):S23–30. doi: 10.1097/MLR.0000000000000060.
    1. Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. BMJ. 2015;350:h1738. doi: 10.1136/bmj.h1738.
    1. Joyce CR, Zutshi DW, Hrubes V, Mason RM. Comparison of fixed interval and visual analogue scales for rating chronic pain. Eur J Clin Pharmacol. 1975;8(6):415–20. doi: 10.1007/BF00562315.
    1. Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The Faces Pain Scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties. Pain. 1990;41(2):139–50. doi: 10.1016/0304-3959(90)90018-9.
    1. Stratford PW, Binkley JM, Riddle DL. Development and initial validation of the Back Pain Functional Scale. Spine. 2000;25(16):2095–102. doi: 10.1097/00007632-200008150-00015.
    1. Stratford PW, Binkley JM. A comparison study of the back pain functional scale and Roland Morris Questionnaire. North American Orthopaedic Rehabilitation Research Network. J Rheumatol. 2000;27(8):1928–36.
    1. Goertz CM, Long CR, Hondras MA, Petri R, Delgado R, Lawrence DJ, et al. Adding chiropractic manipulative therapy to standard medical care for patients with acute low back pain: results of a pragmatic randomized comparative effectiveness study. Spine. 2013;38(8):627–34. doi: 10.1097/BRS.0b013e31827733e7.
    1. Gagne AR, Hasson SM. Lumbar extension exercises in conjunction with mechanical traction for the management of a patient with a lumbar herniated disc. Physiother Theory Pract. 2010;26(4):256–66. doi: 10.3109/09593980903051495.
    1. Wang YC, Hart DL, Werneke M, Stratford PW, Mioduski JE. Clinical interpretation of outcome measures generated from a lumbar computerized adaptive test. Phys Ther. 2010;90(9):1323–35. doi: 10.2522/ptj.20090371.
    1. Hart DL, Mioduski JE, Werneke MW, Stratford PW. Simulated computerized adaptive test for patients with lumbar spine impairments was efficient and produced valid measures of function. J Clin Epidemiol. 2006;59(9):947–56. doi: 10.1016/j.jclinepi.2005.10.017.
    1. Longo UG, Loppini M, Denaro L, Maffulli N, Denaro V. Rating scales for low back pain. Br Med Bull. 2010;94:81–144. doi: 10.1093/bmb/ldp052.
    1. Johannessen T, Fosstvedt D. Statistical power in single subject trials. Fam Pract. 1991;8(4):384–7. doi: 10.1093/fampra/8.4.384.
    1. Egger M, Smith GD, Altman DG, Chalmers I. Systematic reviews in health care: meta-analysis in context. 2. London: BMJ Books; 2001.
    1. Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. J Clin Epidemiol. 2010;63(12):1312–23. doi: 10.1016/j.jclinepi.2010.04.020.
    1. Zucker DR, Schmid CH, McIntosh MW, D’Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol. 1997;50(4):401–10. doi: 10.1016/S0895-4356(96)00429-5.
    1. Scott IA, Gray LC, Martin JH, Pillans PI, Mitchell CA. Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evid Based Med. 2013;18(4):121–4. doi: 10.1136/eb-2012-100930.
    1. Fried TR, McGraw S, Agostini JV, Tinetti ME. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making. J Am Geriatr Soc. 2008;56(10):1839–44. doi: 10.1111/j.1532-5415.2008.01923.x.
    1. Olsen LA, Aisner D, McGinnis JM. The learning healthcare system: workshop summary. Washington DC: National Academies Press; 2007.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner